Related Experiment Video
Updated: Jan 21, 2026

Patient-derived Heterogeneous Xenograft Model of Pancreatic Cancer Using Zebrafish Larvae as Hosts for Comparative Drug Assessment
Published on: April 30, 2019
Sarcopenia: looking to muscle mass to better manage pancreatic cancer patients
Debora Basile1,2, Carla Corvaja1,2, Riccardo Caccialanza3
1Department of Medicine (DAME), University of Udine, Udine.
Purpose Of Review:
Overall survival of patients with pancreatic cancer is strongly conditioned by tumor biology and the incidence of malnutrition and metabolic disorders. In this landscape, the assessment of body composition is crucial to properly manage the clinical implications of muscle wasting. The pathogenesis of this condition is the result of a complex interplay between cancer and the host. In particular, sarcopenia is induced by an inadequate nutritional intake, hormonal abnormalities, inflammation and imbalance between anabolic and catabolic pathways.
Recent Findings:
Recent evidences have highlighted the role of sarcopenia in cancer patients, revealing a prognostic impact on morbidity, mortality and survival.
Summary:
The occurrence of sarcopenia could amplify chemotherapy-induced toxicities, prolong hospitalizations and reduce adherence to anticancer treatment, worsening quality of life and survival. Although considerable efforts have been made to develop treatment strategies, no effective interventions have been identified so far. Nevertheless, if promptly and adequately supported, pancreatic cancer might benefit from adopted dietary intervention to avoid further loss of lean mass.
Related Concept Videos
Acute Pancreatitis II: Clinical Manifestations and Management
Atomic Mass
Molar Mass
Impression Management Techniques I: Managing Appearances
Tonsillitis II: Management
Management of Insomnia

